INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin

Investigational New Drugs

Volumn 26, Issue 1, 2008, Pages 1-5

  Mason, Kathryn A ^a   Valdecanas, David ^a   Hunter, Nancy R ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Doxorubicin; Doxorubicin induced apoptosis; INO 1001; p53 Deficient cancer cells; Poly(ADP ribose)

Indexed keywords

DOXORUBICIN; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38149076469     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9072-5     Document Type: Article

References (23)

1. Althaus FR (1985) ADP-Ribosylation of Proteins. Springer, Berlin
2. Southan GJ, Szabo C (2003) Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 10(4):321-340
3. Beneke S, Diefenbach J, Burkle A (2004) Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer 111(6):813-818
4. Lunee J, George M, Hedges M, Cramp W, Wish W, Hunt B (1984) Post-irradiation sensitization with the ADP-ribosyltransferase inhibitor 3-acetamidobenzamide. Br J Cancer 49:19-25
5. Brown D, Evans J, Brown J (1984) The influence of inhibitors of poly(ADP)polymerase on X-ray induced potentially lethal damage repair. Br J Cancer 49:27-34
6. Ben-Hur B, Utsumi H, Elkind M (1984) Inhibitors of poly(ADP-ribose) synthesis enhance X-ray killing of log phase Chinese hamster cells. Radiat Res 97:546-555
7. Ben-Hur E (1984) Involvement of poly (ADP-ribose) in the radiation response of mammalian cells. Int J Radiat Biol 46(6):659-671
8. Ueno AM, Tanaka O, Matsudaira H (1984) Inhibition of gamma-ray dose-rate effects by D2O and inhibitors of poly(ADP-ribose) synthetase in cultured mammalian L5178Y cells. Radiat Res 98(3):574-582
9. Thraves P, Mossman KL, Brennan T, Dritschilo A (1985) Radiosensitization of human fibroblasts by 3-aminobenzamide: An inhibitor of poly(ADP-ribosylation) . Radiat Res 104(2 Pt 1):119-127
10. Kelland LR, Burgess L, Steel GG (1987) Radiation damage repair capacity of a human germ-cell tumour cell line: inhibition by 3-aminobenzamide. Int J Radiat Biol Relat Stud Phys Chem Med 51(2):227-241
11. Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, Sebolt-Leopold JS (1991) Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res 126(3):367-371
12. Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA (2004) Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205(2):155-160
13. Bowman KJ, White A, Golding B, Griffin R, Curtin N (1998) Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 78(10):1269-1277
14. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin N, Durkacz B, Hostomsky Z, Newell D (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6(7):2860-2867
15. Skalitzky D, Marakovits J, Maegley K, Ekker A, Yu X, Hostomsky Z, Webber S, Eastman B, Almassy R, Li J, Curtin N, Newell D, Calvert A, Griffin R, Golding B (2003) Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 46(2):210-213
16. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96(1):56-67
17. Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, Ruiz de Almodovar JM, De Murcia G, Oliver FJ (2005) PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386(Pt 1):119-125
18. Madhusudan S, Middleton M (2005) The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 31(8):603-617
19. Xiao CY, Chen M, Zsengeller Z, Szabo C (2004) Poly (ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translation of apoptosis-inducing factor. J Pharmacol Exp Ther 310 (2):498-504
20. Xiao CY, Chen M, Zsengeller Z, Li H, Kiss L, Kollai M, Szabo C (2005) Poly (ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther 312(3):891-898
21. Oren M (2003) Decision making by p53: life, death and cancer. Cell Death Differ 10(4):431-442
22. Vogelstein B, Lane D, Levine A (2000) Surfing the p53 network. Nature 408(6810):307-310
23. Wahl GM, Carr AM (2001) The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3(12):E277-286